These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1575 related articles for article (PubMed ID: 12516033)

  • 1. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
    Ferrara N
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of vascular endothelial growth factor in angiogenesis.
    Ferrara N; Gerber HP
    Acta Haematol; 2001; 106(4):148-56. PubMed ID: 11815711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic anti-VEGF antibodies.
    Lien S; Lowman HB
    Handb Exp Pharmacol; 2008; (181):131-50. PubMed ID: 18071944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical implications of angiogenesis in the treatment of cancer.
    Aoun E; Taher A
    J Med Liban; 2002; 50(1-2):32-8. PubMed ID: 12841311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF receptor signaling in tumor angiogenesis.
    McMahon G
    Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of vascular endothelial growth factor in the regulation of angiogenesis.
    Ferrara N
    Kidney Int; 1999 Sep; 56(3):794-814. PubMed ID: 10469350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor and its receptors in multiple myeloma.
    Ria R; Roccaro AM; Merchionne F; Vacca A; Dammacco F; Ribatti D
    Leukemia; 2003 Oct; 17(10):1961-6. PubMed ID: 14513045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
    Rosen LS
    Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
    J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Divergence of angiogenic and vascular permeability signaling by VEGF: inhibition of protein kinase C suppresses VEGF-induced angiogenesis, but promotes VEGF-induced, NO-dependent vascular permeability.
    Spyridopoulos I; Luedemann C; Chen D; Kearney M; Chen D; Murohara T; Principe N; Isner JM; Losordo DW
    Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):901-6. PubMed ID: 12067896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factors and angiogenesis in eye disease.
    Witmer AN; Vrensen GF; Van Noorden CJ; Schlingemann RO
    Prog Retin Eye Res; 2003 Jan; 22(1):1-29. PubMed ID: 12597922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules.
    Zachary I
    IDrugs; 2003 Mar; 6(3):224-31. PubMed ID: 12789611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of the vascular endothelial growth factor receptor.
    Rosen LS
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1173-87. PubMed ID: 12512388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor and the regulation of angiogenesis.
    Ferrara N
    Recent Prog Horm Res; 2000; 55():15-35; discussion 35-6. PubMed ID: 11036931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF: an update on biological and therapeutic aspects.
    Ferrara N
    Curr Opin Biotechnol; 2000 Dec; 11(6):617-24. PubMed ID: 11102799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.